OncoCyte Management
Management criteria checks 3/4
OncoCyte's CEO is Josh Riggs, appointed in Dec 2022, has a tenure of 2.5 years. total yearly compensation is $786.08K, comprised of 49% salary and 51% bonuses, including company stock and options. directly owns 0.012% of the company’s shares, worth $11.64K. The average tenure of the management team and the board of directors is 2.1 years and 4.4 years respectively.
Key information
Josh Riggs
Chief executive officer
US$786.1k
Total compensation
| CEO salary percentage | 48.98% |
| CEO tenure | 2.5yrs |
| CEO ownership | 0.01% |
| Management average tenure | 2.1yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
GraftAssure Assay Submissions Will Unlock Transplant Center Opportunities
Strategic partnerships and anticipated regulatory approvals are poised to significantly expand OncoCyte's market reach, boosting revenue and supporting scalability.Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?
Oct 28
Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test
Aug 30Revisiting OncoCyte Corp.
May 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$58m |
| Dec 31 2024 | US$786k | US$385k | -US$61m |
| Sep 30 2024 | n/a | n/a | -US$44m |
| Jun 30 2024 | n/a | n/a | -US$37m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$725k | US$340k | -US$26m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$514k | US$242k | -US$19m |
Compensation vs Market: Josh's total compensation ($USD786.08K) is about average for companies of similar size in the US market ($USD646.03K).
Compensation vs Earnings: Josh's compensation has increased whilst the company is unprofitable.
CEO
Josh Riggs (42 yo)
Mr. Joshua Riggs, also known as Josh, serves as Director of OncoCyte Corporation since February 28, 2023, serves as its Chief Executive Officer & President since February 24, 2023 to February 2023. He serv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.5yrs | US$786.08k | 0.012% $ 11.6k | |
| Chief Financial Officer | 1yr | US$908.80k | 0.53% $ 502.1k | |
| VP of Accounting | 2.8yrs | US$303.93k | 0% $ 0 | |
| Chief Science Officer | 2.4yrs | US$633.57k | 0.072% $ 68.5k | |
| Chief Technology Officer | 2.1yrs | no data | no data | |
| VP, General Counsel & Secretary | 1.3yrs | no data | no data | |
| Senior Vice President of Business Operations | 1.9yrs | no data | no data | |
| Consulting Chief Medical Officer | less than a year | no data | no data | |
| Scientific Advisor | 9.7yrs | US$328.84k | no data | |
| Sr. Executive Assistant | no data | no data | no data |
Experienced Management: OCX's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.3yrs | US$786.08k | 0.012% $ 11.6k | |
| Independent Director | 2.6yrs | US$151.36k | 0.0055% $ 5.2k | |
| Independent Chairman | 10yrs | US$207.97k | 0.34% $ 322.6k | |
| Member of Scientific & Medical Advisory Board | 4.4yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | 4.4yrs | no data | no data | |
| Independent Director | 9.5yrs | US$151.36k | 0.016% $ 15.0k | |
| Member of Scientific & Medical Advisory Board | 4.4yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | 4.4yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | 4.4yrs | no data | no data |
Experienced Board: OCX's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/02 12:08 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OncoCyte Corporation is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Paul Knight | Janney Montgomery Scott LLC |
| null null | KeyBanc Capital Markets Inc. |